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Abstract 
 
Obesity and obesity-related metabolic diseases are associated with a low-grade inflammation, 
including slightly increased serum levels of the acute phase protein serum amyloid A (A-SAA). 
A-SAA is one amongst several adipose tissue (AT) produced proteins suggested to influence 
development of metabolic diseases. The A-SAA protein may have pro-atherogenic functions, and 
release of A-SAA from the AT may contribute to the development of cardiovascular disease. 
Furthermore, A-SAA is functionally linked to insulin resistance via one of its receptors, selenoprotein 
S (SELS). The tenomodulin (TNMD) gene is expressed in adipose tissue, but its role in obesity is 
unclear. The overall aim of this thesis was to increase our understanding of how TNMD, A-SAA and 
SELS relate to obesity and obesity-associated metabolic diseases. An additional aim was to establish a 
mouse model mirroring the human A-SAA production in AT. 
 
To achieve these goals, we (1) investigated TNMD gene expression in human AT by DNA microarray 
and real-time PCR analysis; (2) analyzed serum levels of A-SAA in a cohort with a wide range in 
body mass index and metabolic parameters; (3) analyzed SELS gene expression and genotyped three 
SELS polymorphisms, previously associated with serum levels of inflammatory markers, in a case-
control study of coronary heart disease and (4) generated a mouse model with transgenic over-
expression of the human SAA1 (hSAA) gene in AT.  
 
The TNMD gene was highly expressed in human AT, with a higher expression in obese compared to 
lean subjects. Furthermore, TNMD gene expression was down-regulated during diet-induced weight 
loss. These data suggest that TNMD plays a role in the adipose tissue. 
Inflammatory markers and measures of glycemic control were strongly associated with serum levels of 
A-SAA. The strongest associations were found in women, and serum levels of A-SAA were associated 
with adipocyte size in women only. These data suggest that sex-specific factors have to be considered 
when analyzing serum levels of A-SAA in relation to metabolic disease. 
Gene expression of SELS in AT was associated with measures of obesity. Furthermore, genetic 
variants in the SELS gene were associated with serum levels of glucose, measures of insulin resistance 
and blood pressure. These findings suggest that SELS plays a role in the development of metabolic 
disease. 
In the hSAA mouse model, hSAA was specifically expressed in AT and plasma levels of hSAA were 
increased in obese mice. The hSAA protein was found to be co-localized to high-density lipoprotein 
containing fractions of plasma.  
 
In conclusion, the results of this thesis suggest that TNMD, A-SAA and SELS have metabolic effects 
that should be further explored. The established hSAA transgenic mouse model opens the possibility 
to further explore the effects of AT-derived A-SAA on cardiovascular disease. 
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